A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors

This article has no abstract
Epistemonikos ID: 984995e7baa460395573a19c8b26900f8f357479
First added on: Feb 05, 2025